You are here

Company Monitoring Page for UCB-Pharma

latest headlines for company on cafepharma

Aducanumab tops 2021’s biggest potential launches

EP Vantage

Mon, 01/18/21 - 01:04 pm

UCB backs epilepsy-focused digital heath startup Nile AI

Pharmaforum

Fri, 01/15/21 - 10:02 am

Tags:

UCB Pharma, digital health, Nile AI, artificial intelligence, epilepsy

UCB accelerates ambitions in gene therapy with two deals

Pharma Letter

Thu, 11/12/20 - 10:51 am

Tags:

gene therapy, UCB Pharma, M&A, Handl Therapeutics, Lacerta Therapeutics

Eli Lilly strikes deal to sell R&D campus to UCB

Fierce Biotech

Fri, 10/16/20 - 11:13 am

Tags:

Eli Lilly, R&D, UK, UCB Pharma

Roche doubles down on Tau

EP Vantage

Wed, 07/29/20 - 12:20 pm

Tags:

Roche, anti-tau antibodies, UCB Pharma, UCB01017, Alzheimer's disease

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Endpoints

Fri, 07/24/20 - 11:17 am

Tags:

UCB Pharma, psoriasis, bimekizumab, Cosentyx

UCB’s growth driver squares up against the competition

EP Vantage

Thu, 06/11/20 - 12:20 pm

Tags:

UCB Pharma, bimekizumab, psoriasis, clinical trials, Novartis, Cosentyx

UCB buys epilepsy firm Engage Tx in $270m deal

PM Live

Mon, 06/8/20 - 10:30 am

Tags:

UCB Pharma, epilepsy, M&A, Engage Therapeutics, drug-device combos, Staccato Alprazolam

UCB to build €300M biologics plant, add 150 workers

Fierce Pharma

Thu, 12/26/19 - 01:13 pm

Tags:

UCB Pharma, biologics, drug manufacturing, Belgium

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Fri, 12/6/19 - 09:31 pm

Tags:

UCB Pharma, bimekizumab, AbbVie, Humira, psoriasis, biosimilars

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

Fri, 11/15/19 - 11:12 am

Tags:

UCB Pharma, bimekizumab, psoriasis, clinical trials

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

Fierce Biotech

Fri, 10/18/19 - 07:47 pm

Tags:

UCB Pharma, bispecific antibodies, bimekizumab, JNJ, Stelara, psoriasis

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Endpoints

Thu, 10/17/19 - 10:24 am

Tags:

UCB Pharma, Amgen, psoriasis, bimekizumab

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

Fierce Biotech

Thu, 10/10/19 - 12:56 pm

Tags:

UCB Pharma, Ra Pharmaceuticals, M&A, zilucoplan, Alexion, Soliris

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Fri, 06/28/19 - 10:04 am

Tags:

Amgen, UCB Pharma, FDA, EMA, Europe, osteoporosis, Evenity, romosozumab

FDA approves Evenity for osteoporosis

BioCentury

Tue, 04/9/19 - 07:03 pm

Tags:

FDA, Evenity, romosozumab, Amgen, UCB Pharma, osteoporosis

UCB Debuts AI Powered Virtual Assistant Parkinson's Disease App

CP WIre

Thu, 11/15/18 - 10:49 am

Tags:

UCB Pharma, Parkinson's Disease, artificial intelligence, mobile apps

Thu, 11/15/18 - 09:18 am

Tags:

UCB Pharma, Parkinson's Disease, AI

Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCB

Fierce Biogen

Tue, 10/23/18 - 01:40 pm

Tags:

UCB Pharma, Biogen, dapirolizumab pegol, vixotrigine, lupus, sciatica

UCB, Biogen admit defeat in PhII lupus trial, adding to a string of late-stage failures in the field

Endpoints

Tue, 10/23/18 - 10:37 am

Tags:

UCB Pharma, Biogen, dapirolizumab pegol, DZP, lupus, clinical trials

Pages

last 30 twitter posts